pre-IPO PHARMA

COMPANY OVERVIEW

SpringWorks Therapeutics is focused on underserved patient populations where there is great medical need. The company plans to move forward potential programs for four diseases, all of which currently have no cure. SpringWorks Therapeutics plans to expand its pipeline by partnering with other life science companies and academic institutions who share in the company’s mission.


LOCATION

  • Stamford, CT, USA
  • Durham, NC, USA

  • THERAPEUTIC AREAS

  • Neurological DIsorders
  • Oncology
  • Rare Diseases

  • WEBSITE

    https://www.springworkstx.com


    CAREER WEBSITE

    https://www.springworkstx.com/become-a-springworker/


    SOCIAL MEDIA


    INVESTORS

    arrowmark-partners bain-capital boxer-capital bvf-partners gsk hbm-healthcare-investments lifearc orbimed perceptive-advisors pfizer-ventures samsara-biocapital


    PRESS RELEASES


    Aug 30, 2019

    SpringWorks Therapeutics Appoints Alan Fuhrman to Its Board of Directors


    Aug 29, 2019

    SpringWorks Therapeutics Receives Breakthrough Therapy Designation for Nirogacestat for the Treatment of Adult Patients with Progressive, Unresectable, Recurrent or Refractory Desmoid Tumors


    Aug 15, 2019

    SpringWorks Therapeutics Announces Appointment of Frank Perier as Chief Financial Officer


    Jun 27, 2019

    SpringWorks Therapeutics Announces Global Clinical Collaboration with GlaxoSmithKline to Evaluate Nirogacestat in Combination with Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma


    Jun 3, 2019

    SpringWorks Therapeutics Announces FDA Fast Track Designation for PD-0325901 for the Treatment of a Severe Form of Neurofibromatosis Type 1


    For More Press Releases


    Google Analytics Alternative